Prognostic impact of the combination of erythropoiesis-stimulating agents to cancer treatment: literature review.

about

Prognostic impact of the combination of erythropoiesis-stimulating agents to cancer treatment: literature review.

Item

http://www.wikidata.org/entity/Q38115153

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Prognostic impact of the combi ...... treatment: literature review.

@en

type

Item

label

Prognostic impact of the combi ...... treatment: literature review.

@en

prefLabel

Prognostic impact of the combi ...... treatment: literature review.

@en

P1476

Prognostic impact of the combi ...... r treatment: literature review

@en

P2093

A Goncalves

http://www.w3.org/2001/XMLSchema#string

F Bertucci

http://www.w3.org/2001/XMLSchema#string

H Errihani

http://www.w3.org/2001/XMLSchema#string

H M'rabti

http://www.w3.org/2001/XMLSchema#string

L Boulaamane

http://www.w3.org/2001/XMLSchema#string

S Boutayeb

http://www.w3.org/2001/XMLSchema#string

P2860

Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer

Early hemoglobin response and alternative metrics of efficacy with erythropoietic agents for chemotherapy-related anemia.

Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients.

Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature.

Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia.

Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.

Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes.

American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer.

Chemotherapy-induced anemia in adults: incidence and treatment.

Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.

P2888

s00520-013-1866-8

P304

2359-2369

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00520-013-1866-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Patrice Viens

P577

2013-06-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23775155

http://www.w3.org/2001/XMLSchema#string